Forbes March 26, 2025
Dr. Marty Makary, President Trump’s pick to lead the U.S. Food and Drug Administration, was confirmed by the Senate Tuesday night by a vote of 56 to 44. One of the first and most consequential challenges he’ll face is determining how the FDA will resolve a battle that pits Novo Nordisk and Eli Lilly, which manufacture hugely popular (and equally expensive) weight loss drugs like Ozempic and Mounjaro, against hundreds of compounding pharmacies that produce lower-cost versions with the same active pharmaceutical ingredients.
Which side Makary takes in this fight could affect tens of billions of dollars in healthcare spending and the health of millions of Americans.
How We Reached This Point
Glucagon-like peptide-1 receptor agonists grew out of National...
Today's Sponsors
Today's Sponsor